Acino Holding AG (FRA:S3H) ROCE % : -3.67% (As of Dec. 2013)

View and export this data going back to . Start your Free Trial

What is Acino Holding AG ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Acino Holding AG's annualized ROCE % for the quarter that ended in Dec. 2013 was -3.67%.

Acino Holding AG ROCE % Historical Data

The historical data trend for Acino Holding AG's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acino Holding AG ROCE % Chart

Acino Holding AG Annual Data

Trend

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

ROCE %

Get a 7-Day Free Trial

15.81

-0.93

2.41

1.86

-3.67

Acino Holding AG Semi-Annual Data
	Dec03	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	Dec13
ROCE %	Get a 7-Day Free Trial						15.81	-0.93	2.41	1.86	-3.67

Acino Holding AG ROCE % Calculation

Acino Holding AG's annualized ROCE % for the fiscal year that ended in Dec. 2013 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2013 )		(A: Dec. 2012 )		(A: Dec. 2013 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2013 )		(A: Dec. 2012 )		(A: Dec. 2013 )
	=	-14.975	/	( ( (505.815 - 84.556)	+	(458.051 - 63.917) )	/ 2 )
	=	-14.975	/	( (421.259	+	394.134)	/ 2 )
	=	-14.975	/	407.6965
	=	-3.67 %

Acino Holding AG's ROCE % of for the quarter that ended in Dec. 2013 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2013 )		(Q: Dec. 2012 )		(Q: Dec. 2013 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2013 )		(Q: Dec. 2012 )		(Q: Dec. 2013 )
	=	-14.975	/	( ( (505.815 - 84.556)	+	(458.051 - 63.917) )	/ 2 )
	=	-14.975	/	( ( 421.259	+	394.134 )	/ 2 )
	=	-14.975	/	407.6965
	=	-3.67 %

(1) Note: The EBIT data used here is one times the annual (Dec. 2013) EBIT data.

Acino Holding AG (FRA:S3H) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Acino Holding AG ROCE % Related Terms

Thank you for viewing the detailed overview of Acino Holding AG's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Acino Holding AG (FRA:S3H) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acino Holding AG (FRA:S3H) » Definitions » ROCE %

Traded in Other Exchanges

N/A

Address

Website

http://www.acino-pharma.com

Acino Holding AG is a Switzerland-based company engaged in the pharmaceutical industry. The Company develops, manufactures, and markets pharmaceuticals in novel drug delivery forms internationally. It is divided into four segments Business to Consumer (BtC); Business to Business (BtB); Technology marketing (TM); and Production (Prod). The BtC segment comprises all direct marketing activities. Under the company's "Acino Switzerland" brand and, with the promise of Swiss quality, the company sells its products in emerging markets around the globe. This reporting segment includes the business purchased from Mepha/Cephalon in the Middle East, Africa, Latin America and Asia. The BtB segment comprises Acino's business with its internally developed products, for which the company also owns the intellectual property rights. Acino develops and produces high-quality medicines with proven active ingredients and modern drug delivery systems and grants licenses for them to leading pharmaceutical and generic pharmaceutical companies worldwide. The technology marketing segment comprises a broad spectrum of fully integrated contract services, including procurement, contract development, production and packaging for companies in the life sciences industry. On behalf of these customers, Acino develops a comprehensive product pipeline on the basis of its special technological know-how. This includes both new types of medicines as well as projects with innovative drug delivery systems for established active ingredients. The production segment is responsible for the manufacturing of products and the supplying of the other three segments, and generates turnover through the reimbursement of its services. The manufacturing costs of products are credited to the production segment at standard prices along with remuneration in the form of a mark-up for materials and production costs.

Acino Holding AG (FRA:S3H) Headlines

No Headlines